This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Feb;18(2):160-161.

doi: 10.1016/S1470-2045(16)30675-1. Epub 2017 Jan 10.

Checkpoint inhibition: a new beginning for urothelial cancer

Tracy L Rose¹, Matthew I Milowsky²

Affiliations

Affiliations

¹ Department of Medicine, Division of Hematology/Oncology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: matt_milowsky@med.unc.edu.
² Department of Medicine, Division of Hematology/Oncology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.

PMID: 28081913
DOI: 10.1016/S1470-2045(16)30675-1

Comment

Checkpoint inhibition: a new beginning for urothelial cancer

Tracy L Rose et al. Lancet Oncol. 2017 Feb.

. 2017 Feb;18(2):160-161.

doi: 10.1016/S1470-2045(16)30675-1. Epub 2017 Jan 10.

Authors

Tracy L Rose¹, Matthew I Milowsky²

Affiliations

¹ Department of Medicine, Division of Hematology/Oncology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: matt_milowsky@med.unc.edu.
² Department of Medicine, Division of Hematology/Oncology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.

PMID: 28081913
DOI: 10.1016/S1470-2045(16)30675-1

No abstract available

PubMed Disclaimer

Comment on

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH. Plimack ER, et al. Lancet Oncol. 2017 Feb;18(2):212-220. doi: 10.1016/S1470-2045(17)30007-4. Epub 2017 Jan 10. Lancet Oncol. 2017. PMID: 28081914 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations